Clinical trials: copd or chronic obstructive
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
COPD
TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
Efficacy of TRIMBOW® pMDI and RELVAR® ELLIPTA® DPI on lung stiffness reduction assessed through area under the reactance curve (AX) using oscillometry in chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04671355
- Testing
- Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg, Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
- Conditions
- COVID-19, Chronic Bronchitis, COPD
- Trial name
- NCT05104216
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
COPD
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF…
- Trial name
- NCT01730404
- Testing
- CHF6001 DPI, Roflumilast
- Where
- 5 sites in Ireland, United Kingdom
- Volunteers
- 55 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
This study will assess the efficacy and safety of glycopyrronium bromide (NVA237) in patients with stable COPD, in comparison to an active comparator.
- Trial name
- NCT00501852
- Testing
- NVA237, Tiotropium
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
The study will evaluate the pharmacokinetics (PK) of AZD6793 when administered alone and in combination with itraconazole in healthy adult participants.
- Trial name
- NCT06494644
- Testing
- AZD6793, Itraconazole, AZD6793+ Itraconazole
- Where
- Germany
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of the study is to evaluate the effect of CNTO6785 compared with placebo in participants with moderate to severe Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01966549
- Testing
- CNTO 6785
- Where
- 44 sites in Czechia, Germany and 6 more
- Volunteers
- 187 people
- Sponsor
- Janssen Research & Development, LLC
COPD (Chronic Obstructive Pulmonary Disease)
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characteristics of participants newly initiated with dupilumab for COPD.
- Trial name
- STRIDE (NCT07612878)
- Testing
- Cohort 1: Dupilumab, Cohort 2: usual care only
- Where
- 7 sites in United States
- Volunteers
- 350 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
Safety, Blood Levels and Effects of GW642444
GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00469040
- Testing
- GW642444M for 14 days
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase IIa, open-label, repeat-dose trial to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide/Formoterol Fumarate 400/12 μg in 20 Chinese male…
- Trial name
- NCT03276078
- Testing
- Aclidinium Bromide/Formoterol Fumarate 400/12μg BID
- Where
- China
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT02242279
- Testing
- BEA 2180 BR, Tiotropium
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Indacaterol EfectIveness In COPD Patients With Tuberculosis History
This clinical study will assess efficacy and safety of indacaterol (150㎍ o.d.) in patients with Chronic Obstructive Pulmonary Disease (COPD) with destroyed lung by tuberculosis.
- Trial name
- INFINITY (NCT01778062)
- Testing
- Indacaterol, Control
- Where
- 13 sites in South Korea
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic
Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
When using the Breathe Technologies Ventilation System during simulated activities of daily living (ADLs), Subjects with moderate-to-severe chronic obstructive pulmonary Disease (COPD) will be comfortable and report acceptability.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Airflow Obstruction, Chronic, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease
- Trial name
- PRIDE (NCT01355978)
- Testing
- Noninvasive Open Ventilation System
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Breathe Technologies, Inc.
COPD Patients
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- RISE (NCT02157935)
- Testing
- Symbicort, Formoterol turbohaler
- Where
- 371 sites in United States, Argentina and 9 more
- Volunteers
- 2,026 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113373 (NCT01313650)
- Testing
- 62.5/25mcg, 62.5mcg, 25mcg
- Where
- 165 sites in United States, Bulgaria and 11 more
- Volunteers
- 1,538 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol
In this 5-months study, the response of patients to salbutamol at baseline will be compared with their response to treatment with indacaterol.
- Trial name
- REVERBREZ (NCT01272362)
- Testing
- Indacaterol
- Where
- 137 sites in France
- Volunteers
- 625 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects
The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast 500 μg in healthy Chinese subjects.
- Trial name
- NCT01354782
- Testing
- Roflumilast
- Where
- China
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Migraine
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with…
- Trial name
- NCT02905227
- Testing
- CVT-427 (zolmitriptan inhalation powder)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
COPD
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
To evaluate changes in activity based on the use of portable oxygen concentrators combined with standard of care (SOC) long- term oxygen therapy versus SOC long-term oxygen therapy alone at 12 weeks in patients with COPD who…
- Trial name
- POC-STEP (NCT03513068)
- Testing
- Portable Oxygen Concentrator (POC)
- Where
- 11 sites in United States
- Volunteers
- 108 people
- Sponsor
- ResMed
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.